2026 Annual Meeting | Industry Therapeutic Update from Avidity Biosciences: Bridging Research, Policy, and Practice: Accelerating Diagnosis to Optimize Outcome Potential in Rare Genetic Diseases

Date Monday 04/20/26

Time 06:00 PM - 08:00 PM CDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology, Neuromuscular and Clinical Neurophysiology (EMG)

Learning Objectives • Highlight critical importance of early identification in rare genetic diseases, including role of GC/T in reducing diagnostic delay and empowering informed decision-making • Discuss evolving approaches to screening and monitoring in DMD, and learnings from SMA that may be applied to advance the patient journey • Emphasize urgency of early diagnosis and timely referral to NMD specialists to optimize outcomes • Discuss the potential role of biomarkers in understanding disease activity and response (e.g., CK in DMD)

CME Available No CME available

Event Timeline
11:45 AM - 12:45 PM CDT	Speaker	Industry Therapeutic Update from Avidity Biosciences: Bridging Research, Policy, and Practice: Accelerating Diagnosis to Optimize Outcome Potential in Rare Genetic Diseases

Faculty Disclosures
Kevin M. Flanigan, MD, FAAN	Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Solid. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Armatus. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avidity. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dyne. The institution of Dr. Flanigan has received research support from Ultragenyx . The institution of Dr. Flanigan has received research support from Solid Biosciences. The institution of Dr. Flanigan has received research support from Dyne Therapeutics. The institution of Dr. Flanigan has received research support from Avidity.
Kelsey Johnson	No disclosure on file
Erika L. Finanger, MD	Dr. Finanger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta Therapeutics. Dr. Finanger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PTC Therapeutics. Dr. Finanger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Reata. Dr. Finanger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer.

��ɫ��

��ɫ��